Japanese Drugmaker Accelerates Development of Alzheimer's Drug

Share this content:

the Psychiatry Advisor take:

Fujifilm Holdings Corporation is to accelerate the development of an  Alzheimer's Disease drug "T-817MA" after beginning a Phase II clinical trial in late May. T-817MA offers protection for neurons, promotes neurite outgrowth, and has demonstrated strong efficacy in animal models. The company is further accelerating  development of T-817MA through joint research with the Kyoto University Center for iPS Cell Research and Application.

Japanese Drugmaker Accelerates Development of Alzheimer's Drug
Japanese Drugmaker Accelerates Development of Alzheimer's Drug
Fujifilm Holdings Corporation is to accelerate the development of the Alzheimer's Disease drug "T-817MA" following the commencement of a Phase II clinical trial in late May by its group company, Toyama Chemical, in Japan. In the United States, Fujifilm Corporation entered into a partnership with ...
READ FULL ARTICLE From Medical Express
You must be a registered member of Psychiatry Advisor to post a comment.

Sign Up for Free e-newsletters